Effect of arundic acid on serum S-100β in ischemic stroke

  • L. Creed Pettigrew
  • , Scott E. Kasner
  • , Mark Gorman
  • , Richard P. Atkinson
  • , Yosuke Funakoshi
  • , Hideyasu Ishibashi

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

We prospectively examined the effect of arundic acid (AA; ONO-2506) on S-100β, an astrocyte-derived protein, in a phase I acute stroke study. Subjects with acute ischemic stroke were randomized to daily infusion of AA or placebo for 7 days. Serum S-100β levels were assayed pre-infusion on Days 1-7 and post-infusion on Days 1, 3, and 7, and correlated with National Institutes of Health Stroke Scale (NIHSS). Samples were obtained from 86 subjects (46 AA, 40 placebo). Increase in S-100β protein level from baseline was less in the AA cohort than in the placebo cohort at 7 (p = 0.0471; t-test) and 12 (p = 0.0095)-hours post-infusion on Day 3. Baseline NIHSS correlated with maximal S-100β levels between Days 1 and 3 in the AA (r = 0.51; p = 0.0003) and placebo (r = 0.41; p = 0.0084) cohorts and in the pooled aggregate (n = 86; r = 0.46; p < 0.0001). The same correlations were observed between Day 10 NIHSS and Day 1-3 maximum serum S-100β levels. Treatment with AA was associated with lower serum levels of S-100β after acute ischemic stroke. Our results showing correlation between S-100β and NIHSS indicate that this protein is a clinically relevant marker of neurological deficit in acute stroke.

Original languageEnglish
Pages (from-to)57-61
Number of pages5
JournalJournal of the Neurological Sciences
Volume251
Issue number1-2
DOIs
StatePublished - Dec 21 2006

Bibliographical note

Funding Information:
Financial support for this work was provided by Ono Pharma USA Inc., of Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, ELS, for manuscript preparation and editing.

Funding

Financial support for this work was provided by Ono Pharma USA Inc., of Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, ELS, for manuscript preparation and editing.

FundersFunder number
Ono Pharma USA Inc.
University of Kentucky General Clinical Research Center
National Institutes of Health (NIH)
National Center for Research ResourcesM01RR002602

    Keywords

    • Arundic acid
    • Astrocyte
    • Cerebral ischemia
    • S-100 protein

    ASJC Scopus subject areas

    • Neurology
    • Clinical Neurology

    Fingerprint

    Dive into the research topics of 'Effect of arundic acid on serum S-100β in ischemic stroke'. Together they form a unique fingerprint.

    Cite this